We have carefully examined the frequency of guanidine-resistant revertants in six different clonal pools of guanidine-dependent mutants of type 1 poliovirus. The mutation frequency was (6.5 6.3) x 10-4 (with all amino acid substitutions occurring at position 227). The minimal corrected base substitution frequency per single nucleotide site in the codon for amino acid 227 was (2.1 ± 1.9) x 104.
10-4 at a defined site of the Qp genome (2) , significantly different error frequency estimates have been obtained when studying different viruses or utilizing different experimental approaches. For example, Durbin and Stollar reported a frequency of reversion of less than 5 x 10-6 (16) for a particular host range mutant of Sindbis virus. This is a much lower frequency than is suggested from studies with monoclonal antibody-resistant mutants of Sindbis virus (49) . Parvin et al. (34) have calculated error frequencies of 7.6 x 10-' and less than 10-6 for viable mutants of influenza A virus and poliovirus, respectively. A similar low error frequency of about 2.5 x 10-6 was estimated for the reversion of a poliovirus amber mutant (43) . In contrast, higher mutation frequencies of resistance to monoclonal antibody neutralization, in the range of 10-3 to 10-', have been reported for poliovirus (3, 10, 19, 21, 31) . Also, Ward et al. (54) measured error frequencies of 7 x 10-4 to 5 x 10' with synthetic templates in vitro. Steinhauer et al. (50) have estimated base substitution frequencies between 10' and 10-4 at several single selected sites in total (viable and nonviable) genomes of vesicular stomatitis virus. The same values were found both under equilibrium conditions, in which little consensus sequence evolution was observed because of stabilizing selection, and under conditions in which selective pressure was applied during rapid RNA virus genome evolution (51) .
An alternative approach to the measurement of nucleotide substitution frequencies is to determine the frequency of variants in a cloned population of virus that is resistant to inhibitors of virus replication (for a recent review, see reference 11). One of these drugs, guanidine hydrochloride, at millimolar levels (0.1 to 2 mM) selectively blocks the growth of many picornaviruses including poliovirus (7, 8, 28, 40) . Although guanidine inhibits several virus-induced pro-* Corresponding author.
cesses (35, 57) , its primary action is at the RNA synthesis step (5-7, 24, 33, 53) .
Recent genetic and biochemical evidence suggests that the nonstructural viral polypeptide 2C is responsible for the guanidine sensitivity (20, (36) (37) (38) 42) . Poliovirus type 1 variants with several degrees of resistance to the drug as well as guanidine-dependent mutants have been described, and the corresponding mutations have been mapped in the protein 2C (36, 37) . In addition, infectious cDNA clones that included the relevant mutations yielded the expected phenotypes, thus indicating the direct involvement of 2C (37) in the guanidine trait.
The observed mutation frequency of poliovirus type 1 to a high degree of resistance to guanidine was 7.8 x 10-5 to 4 x 10-8 (36) . This is consistent with a requirement for several mutational steps, as observed by genomic sequencing (36, 37) . Interestingly, those variants resistant to high levels (2 mM) of guanidine (GuaR) showed one single amino acid substitution, Asn-179 -* Gly or Asn-179 --Ala in 2C, involving two nucleotide substitutions in each case (36 A260 Oligonucleotide primers and sequencing protocol. We used the primers X1 and X2 described by Pincus et al. (36) . The viral RNAs were sequenced by dideoxy-chain termination (41) . The observed in the absence of guanidine for any of the six GD1 clonal pools. Table 2 gives the estimates of mutation frequencies (GD1 GuaR) for the six independent GD1 clonal pools. The results were very reproducible in the three experiments performed on each GD1 clonal pool, and the averages obtained with the different GD1 clonal pools did not show statistically significant differences. The range of values obtained was 2.5 x 10-' to 9.0 x 10'.
Characterization of GuaR variants generated during the replication of GD1 in HeLa cells. The estimates of frequencies of mutation GD1 -+ GuaR derived here are based on the assumption that the plaque assay in the absence of guanidine gives an accurate measure of the proportion of GuaR variants that were generated during the infection of a HeLa cell monolayer with a GD1 clonal pool. To verify that we were using a reliable assay, we analyzed four independent plaques (developed in the absence of guanidine) from each of the six GD1 clonal pools. All of the 24 plaques displayed the following properties expected for authentic guanidine-resistant variants (Table 3 Table 3 . We used the primers X1 and X2 of Pincus et al. (36) (Table 4) .
These results indicate that the target site, for mutations involved in the generation of GuaR during the replication of GD1 in HeLa cells, is located at the expected position and that its size spans only 3 bases in the genomic RNA.
Competition among GD1 and GuaR. Finally, we examined the possibility of an overestimation of the frequency of mutation GD1 -* GuaR as a consequence of a selective advantage of GuaR variants. A GuaR variant produced as a result of a polymerase error during the replication of GD1 might exhibit a selective advantage and significantly overgrow the GD1 virus. If so, the final proportion of GuaR would not just measure the frequency of mutation GD1 --GuaR but rather would measure the combined result of mutation plus selection. To investigate to what extent, if any, our estimates of frequencies of mutation were affected by a possible selective advantage of GuaR, we performed competition assays among GD1 and GuaR variants derived from the former.
Under our experimental conditions, GuaR mutants show no significant selective advantage over the GD1 parental mutants (Fig. 1) . In these experiments, we used at least one representative of each class of GuaR variant distinguished by sequence differences at position 227 (Table 4) . We observed no selective advantages by using either high or low multiplicity of infection.
DISCUSSION
In this study, we carefully determined the frequency of mutation at a specific site of the poliovirus genome. Misincorporation frequencies were in the range of 10-4 to 10-3, which was significantly higher than some values previously reported (34, 43). To obtain reliable values, we took several precautions. First, our estimates are based on the analysis of several independent (six) GD1 clonal pools. The use of one single clone might introduce a significant bias in the results. This is because, as the quasispecies structure model for RNA viral population predicts (13), a particular clone could carry an additional mutation that (without being directly related to the guanidine sensitivity phenotype) could affect either the fidelity of RNA replication or the fitness of the considered variant because of the specific combination of mutations. The analysis of several GD1 clonal pools minimizes this problem. We bypassed another potential bias by avoiding the amplification of GuaR variants already present in our GD1 clonal pool stocks.
We exercised great care to obtain accurate plaque assays. Every dilution was plated in triplicate, and the assay was repeated when any ambiguous result was obtained (for example, a difference greater than 10% among the numbers of plaques scored within a triplicate). In addition, each clone was assayed in three independent experiments ( Table 2) . The results show very reproducible figures not only within each of the six clonal pools but also among them (standard deviations did not exceed 34% of the averages given in Table  2 ).
Phenotypic characterization of 24 plaques selected in the absence of guanidine showed that all of them displayed the properties expected for GuaR variants (Table 3) . Moreover, sequence analysis of all 24 clones revealed a single base substitution at the expected amino acid position 227. The characterization of sensitivity to guanidine was extended to 50 plaques obtained in the absence of the drug from one GD1 clonal pool. All displayed the expected GuaR properties, while 20 plaques from the same GD1 clonal pool but isolated in the presence of guanidine did not. A binomial distribution analysis predicts that 94% of the plaques developed in the absence of guanidine (with 95% confidence) are authentic GuaR. In addition, GD1 variants do not replicate in the absence of guanidine (Table 3) . A productive infection with GD1 under these conditions occurs at high multiplicity as expected because of GuaR mutants which are already present in the viral input (Table 3) .
Our sequencing data (Table 3) , in agreement with previous reports (36, 38) (Table 3 ). In addition, we are scoring only viable mutations, which represent some fraction of the total mutations (viable and nonviable). The averages of titrations in the presence and absence of 2 mM guanidine were (3.9 ± 1.3) x 109 and (1.9 ± 0.8) x 106, respectively. The GuaR mutation frequency at amino acid 227 of the poliovirus genome was (6.5 ± 6.3) x 10-4. Three determinations of mutation frequencies were done with each of the six GD1 clonal pools, for a total of eighteen determinations. Presently, we have begun to employ the same approach previously described for vesicular stomatitis virus (50) to estimate the total mutation frequency (viable and nonviable) at several other specific sites of the poliovirus genome.
The ability of poliovirus to mutate under different biological conditions has been well documented (25, 26, 30) , and considerably high mutation frequencies to monoclonal antibody resistance have been reported (3, 10, 19, 21, 31) . However, the target sizes for mutations and viral passage histories were often not defined in these studies. This makes it difficult to derive reliable estimates of mutation frequency from them. The same phenomena, namely extensive heterogeneity and potential for rapid evolution, have been documented for other picomaviruses such as foot-and-mouth disease virus (22, 47; Domingo et (50, 51) . It is possible that all RNA viruses have relatively high mutation rates and that differences among viruses in their rates of variation (and evolution) reflect differences in selective forces rather than in the mutation rates themselves. We cannot exclude the possibility that under certain conditions viruses can display an increase (or decrease) in mutation rates nor that different RNA viruses might have different mutation rates, nor that these rates might vary considerably at different genome sites. Much more work will be required to examine these possibilities.
